Iri

Bridelia ferruginea stem bark and leaf extracts are rich in phenolics (up to 193.58 mg GAE/g) and flavonoids that exert antioxidant, anticholinesterase, antityrosinase, antimicrobial, and antidiabetic effects through radical scavenging and multi-enzyme inhibition. In preclinical models, a tannin-enriched leaf fraction administered at 200 mg/kg significantly reduced basal blood glucose in fructose-induced diabetic mice, while stem bark methanolic extracts achieved antibacterial MIC values as low as 2.48 µg/mL against Gram-positive and Gram-negative pathogens.

Origin & History

Bridelia ferruginea is a deciduous shrub or small tree native to tropical West and Central Africa, widely distributed across Nigeria, Ghana, Côte d'Ivoire, Cameroon, and neighboring countries. It thrives in savanna woodlands, forest margins, and secondary bush, tolerating seasonal drought and a range of soil types typical of the West African tropics. The plant is not commercially cultivated but is harvested from wild stands, with stem bark, leaves, and roots collected for use in traditional Yoruba and other African medicine systems.

Historical & Cultural Context

Bridelia ferruginea holds a recognized place in Yoruba ethnomedicine in southwestern Nigeria, where it is called 'iri' and preparations of the stem bark and leaves are used to manage insomnia, serve as an antibacterial mouthwash for oral and dental complaints, and treat gonorrhea, reflecting the plant's perceived broad-spectrum antimicrobial and sedative properties. The plant is also referenced in the traditional medicine practices of other West African ethnic groups across Ghana, Côte d'Ivoire, and Cameroon for wound healing, fever reduction, and gastrointestinal complaints, though the specific preparation methods and dosing conventions vary by region and have not been uniformly documented in ethnobotanical literature. Stem bark is the most commonly used plant part, typically prepared as a water decoction by boiling or cold maceration, while leaves are sometimes prepared as poultices for topical applications. The plant's widespread traditional use across multiple independent African healing traditions lends ethnopharmacological credibility to the antimicrobial and antidiabetic directions of current laboratory research.

Health Benefits

- **Antioxidant Protection**: Stem bark methanolic extract delivers exceptionally high ABTS radical scavenging capacity (up to 804.22 mg TEAC/g) and FRAP reducing power (up to 633.44 mg/g), driven by dense phenolic content (193.58 mg GAE/g), which may protect cells against oxidative stress-related damage.
- **Antimicrobial Activity**: Stem bark methanolic extract inhibits Escherichia coli and Gram-positive bacteria at MIC values of 2.48–62.99 µg/mL and fungi at 4.96–62.99 µg/mL, supporting its traditional use as a mouthwash for oral infections and as a treatment for gonorrhea in Yoruba ethnomedicine.
- **Antidiabetic Effects**: A tannin fraction isolated from leaves reduced basal blood glucose levels in fructose-induced diabetic mice at 200 mg/kg, likely through ferric ion (Fe³⁺) reduction, antioxidant mechanisms, and inhibition of α-amylase (up to 0.94 mmol ACAE/g) and α-glucosidase (up to 6.24 mmol ACAE/g), slowing carbohydrate digestion.
- **Anticholinesterase Activity**: Extracts inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), enzymes responsible for degrading the neurotransmitter acetylcholine; this mechanism is pharmacologically relevant to cognitive support and is the same target exploited by approved dementia medications, though clinical translation for iri remains unestablished.
- **Antityrosinase and Skin-Protective Effects**: Stem bark methanolic extract inhibits tyrosinase at 157.07 ± 0.37 mg KAE/g, the rate-limiting enzyme in melanin biosynthesis, suggesting potential utility in managing hyperpigmentation disorders, though this evidence is entirely in vitro.
- **Antiproliferative Potential**: In vitro testing on HCT116 human colon cancer cells demonstrated antiproliferative activity of Bridelia ferruginea extracts, an effect attributed to the combined pro-oxidant and cytotoxic actions of high-density polyphenols and tannins, though no animal or human cancer studies have been conducted.
- **Sedative and Sleep-Supportive Use**: Traditional Yoruba practitioners use preparations of Bridelia ferruginea to treat insomnia, a use that may correspond to central nervous system modulation by phenolic compounds, potentially via cholinergic or GABAergic pathways, though no mechanistic or clinical data yet confirm this application.

How It Works

Phenolics and tannins in Bridelia ferruginea extracts donate hydrogen atoms or electrons to neutralize free radicals (DPPH, ABTS) and reduce ferric iron (Fe³⁺ to Fe²⁺), protecting cellular macromolecules from oxidative damage as confirmed by DPPH values of 95.26–491.59 mg TEAC/g and FRAP up to 633.44 mg/g across leaf and stem bark extracts. Flavonoids and tannin fractions competitively inhibit α-amylase and α-glucosidase—enzymes that hydrolyze dietary starch to absorbable glucose—thereby blunting postprandial glycemia, with α-glucosidase inhibition particularly potent in ethyl acetate fractions (up to 6.24 mmol ACAE/g). The extracts inhibit acetylcholinesterase and butyrylcholinesterase, prolonging synaptic acetylcholine availability, and suppress tyrosinase (up to 157.07 mg KAE/g in stem bark), the copper-dependent enzyme catalyzing the first steps of melanogenesis. Antimicrobial action is attributed to phenolic disruption of microbial membrane integrity and inhibition of essential bacterial enzymes, producing MIC values as low as 2.48 µg/mL, consistent with high-density tannin and phenolic loading in the stem bark.

Scientific Research

The current evidence base for Bridelia ferruginea is limited exclusively to in vitro biochemical assays and one preclinical rodent study; no human clinical trials have been registered or published as of the available literature. In vitro studies have systematically characterized antioxidant capacity, enzyme inhibition (AChE, BChE, tyrosinase, α-amylase, α-glucosidase), and antimicrobial potency using standardized assays (DPPH, ABTS, FRAP, MIC broth microdilution) across multiple solvent extracts (methanol, water, ethyl acetate) of both leaves and stem bark. One preclinical animal study evaluated a tannin-enriched leaf fraction at 200 mg/kg in a fructose-induced mouse model of hyperglycemia, reporting significant blood glucose reduction without quantifying exact effect size or p-value in the available abstract. Antiproliferative activity against HCT116 colon cancer cells has been reported in vitro, but no mechanistic pathway studies, pharmacokinetic data, or dose-response curves in living organisms have been published for this endpoint.

Clinical Summary

No human clinical trials have been conducted on Bridelia ferruginea or any of its isolated fractions as of the current literature. The sole in vivo intervention identified is a murine antidiabetic study using 200 mg/kg of a tannin fraction in fructose-induced diabetic mice, which reported statistically significant blood glucose lowering without provision of confidence intervals, effect sizes, or histopathological outcomes. All antimicrobial, antioxidant, anticholinesterase, antityrosinase, and antiproliferative findings derive from cell-free or cell-line assays, which cannot substitute for pharmacokinetic, pharmacodynamic, or safety data in humans. Confidence in clinical translation is very low; the evidence warrants mechanistic and toxicological animal studies as prerequisites to any human trial design.

Nutritional Profile

Bridelia ferruginea is not consumed as a food and has no established macronutrient or micronutrient profile as a dietary source. Phytochemically, the stem bark is the most phenolic-dense part, with total phenolic content reaching 193.58 ± 0.98 mg GAE/g in methanolic extract and 187.84 ± 1.88 mg GAE/g in aqueous extract — values that rank among the highest reported for African medicinal plants in comparative studies. Total flavonoid content is highest in leaf extracts (42.31 ± 0.39 mg RE/g in methanolic leaf extract) compared to stem bark (2.05–2.62 mg RE/g), suggesting organ-specific biosynthesis patterns. Tannins (condensed and hydrolysable types) are prominent in both bark and leaf fractions and are considered the primary bioactive class responsible for antidiabetic and antioxidant activities; no data on bioavailability, metabolite profiles, or absorption kinetics in humans are available.

Preparation & Dosage

- **Traditional Aqueous Decoction (Mouthwash)**: Stem bark is boiled in water and the cooled liquid is used as an oral rinse for dental infections and gonorrheal urethritis management in Yoruba traditional practice; no standardized concentration is established.
- **Traditional Insomnia Preparation**: Bark or leaf decoctions are consumed orally in folk medicine for sleep induction; dose and preparation ratios are not documented in peer-reviewed sources.
- **Methanolic Extract (Research Grade)**: Used in laboratory studies at concentrations yielding MIC values of 2.48–62.99 µg/mL; not commercially available as a supplement.
- **Tannin Fraction (Preclinical Reference Dose)**: 200 mg/kg body weight administered orally to mice in an antidiabetic study; human equivalent dose extrapolation has not been validated and should not be self-administered.
- **Ethyl Acetate Extract (Research Grade)**: Demonstrates highest α-glucosidase inhibition (up to 6.24 mmol ACAE/g); no commercial formulation exists.
- **Standardization**: No standardization percentages for phenolics, tannins, or flavonoids have been established for any commercial or therapeutic application.

Synergy & Pairings

The combination of α-glucosidase inhibitory activity in Bridelia ferruginea ethyl acetate extracts with other plant-derived antidiabetic agents such as berberine (from Berberis species) or bitter melon (Momordica charantia) may produce additive postprandial glucose-lowering effects through complementary enzyme inhibition and insulin-sensitizing pathways, though this has not been tested experimentally. The antioxidant phenolics in iri could theoretically enhance the efficacy of antimicrobial formulations by neutralizing oxidative bacterial defenses, and pairing with quercetin-rich botanicals may amplify ABTS and DPPH scavenging capacity through phenolic synergism. No validated clinical or preclinical combination studies involving Bridelia ferruginea have been published.

Safety & Interactions

No formal toxicological studies, safety pharmacology evaluations, or adverse event data have been published for Bridelia ferruginea extracts in humans or animals beyond the single murine antidiabetic study, which did not report organ toxicity or hematological outcomes. The high tannin content in stem bark and leaf extracts presents a theoretical risk of gastrointestinal irritation, reduced absorption of minerals (iron, zinc) and certain medications if consumed in large quantities, consistent with known tannin pharmacology. No drug interaction studies exist; however, given demonstrated α-amylase, α-glucosidase, and acetylcholinesterase inhibitory activity, concurrent use with antidiabetic agents (metformin, acarbose) or cholinesterase inhibitors (donepezil, rivastigmine) could theoretically produce additive or synergistic effects requiring monitoring. No data are available to guide use in pregnancy, lactation, pediatric populations, or individuals with hepatic or renal impairment, and self-medication with crude preparations cannot be recommended on the current evidence base.